Summary

Fibromyalgia Treatment Market – Scope of Report
TMR’s report on the global fibromyalgia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global fibromyalgia treatment market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fibromyalgia treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the fibromyalgia treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global fibromyalgia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global fibromyalgia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global fibromyalgia treatment market.

The report delves into the competitive landscape of the global fibromyalgia treatment market. Key players operating in the global fibromyalgia treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global fibromyalgia treatment market profiled in this report.

Key Questions Answered in Global fibromyalgia treatment Market Report
• What is the sales/revenue generated by fibromyalgia treatment across all regions during the forecast period?
• What are the opportunities in the global fibromyalgia treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Fibromyalgia Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global fibromyalgia treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global fibromyalgia treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global fibromyalgia treatment market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fibromyalgia Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Fibromyalgia Treatment Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Fibromyalgia Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017-2031
6.3.1. Medications
6.3.1.1. Pain Relievers
6.3.1.2. Anti-Depressants
6.3.1.3. Anti-Seizure Drugs
6.3.2. Therapies
6.3.2.1. Physical Therapy
6.3.2.2. Occupational Therapy
6.3.2.3. Counselling
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Fibromyalgia Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017-2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Fibromyalgia Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Fibromyalgia Treatment Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment Type, 2017-2031
9.3.1. Medications
9.3.1.1. Pain Relievers
9.3.1.2. Anti-Depressants
9.3.1.3. Anti-Seizure Drugs
9.3.2. Therapies
9.3.2.1. Physical Therapy
9.3.2.2. Occupational Therapy
9.3.2.3. Counselling
9.4. Market Value Forecast, by Distribution Channel, 2017-2031
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Value Forecast, by Country, 2017-2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment Type
9.6.2. By Distribution Channel
9.6.3. By Country
10. Europe Fibromyalgia Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2017-2031
10.3.1. Medications
10.3.1.1. Pain Relievers
10.3.1.2. Anti-Depressants
10.3.1.3. Anti-Seizure Drugs
10.3.2. Therapies
10.3.2.1. Physical Therapy
10.3.2.2. Occupational Therapy
10.3.2.3. Counselling
10.4. Market Value Forecast, by Distribution Channel, 2017-2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Distribution Channel
10.6.3. By Country/Sub-region
11. Asia Pacific Fibromyalgia Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2017-2031
11.3.1. Medications
11.3.1.1. Pain Relievers
11.3.1.2. Anti-Depressants
11.3.1.3. Anti-Seizure Drugs
11.3.2. Therapies
11.3.2.1. Physical Therapy
11.3.2.2. Occupational Therapy
11.3.2.3. Counselling
11.4. Market Value Forecast, by Distribution Channel, 2017-2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Distribution Channel
11.6.3. By Country/Sub-region
12. Latin America Fibromyalgia Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2017-2031
12.3.1. Medications
12.3.1.1. Pain Relievers
12.3.1.2. Anti-Depressants
12.3.1.3. Anti-Seizure Drugs
12.3.2. Therapies
12.3.2.1. Physical Therapy
12.3.2.2. Occupational Therapy
12.3.2.3. Counselling
12.4. Market Value Forecast, by Distribution Channel, 2017-2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Distribution Channel
12.6.3. By Country/Sub-region
13. Middle East & Africa Fibromyalgia Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2017-2031
13.3.1. Medications
13.3.1.1. Pain Relievers
13.3.1.2. Anti-Depressants
13.3.1.3. Anti-Seizure Drugs
13.3.2. Therapies
13.3.2.1. Physical Therapy
13.3.2.2. Occupational Therapy
13.3.2.3. Counselling
13.4. Market Value Forecast, by Distribution Channel, 2017-2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Distribution Channel
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Pfizer Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Eli Lilly and Company
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. AbbVie Inc.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Tonix Pharmaceuticals
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Aptinyx Inc.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Teva Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Novartis AG
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Sun Pharmaceutical Industries Limited
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Astellas Pharma Inc.
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Nipro Corporation
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview